InsiderPulse
Dashboard

KRYS

Krystal Biotech, Inc.

Health CareRussell 2000

Krystal Biotech, Inc. insider trading

Krystal Biotech, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Pittsburgh, PA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent KRYS insider transactions

2 insiders traded KRYS on the open market on Sep 04, 2026 — 24 sales worth $17.5M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$17.5M

24 of 24 on a 10b5-1 plan

Net
−$17.5M
Insiders
2

Open-market purchases (code P) and sales (code S) from Krystal Biotech, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every KRYS Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

KRYS insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 6 insiders traded KRYS on the open market: 0 purchases and 222 sales worth $148.2M, 220 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 137 sales ($94.1M), by 6 insiders.

QuarterBoughtSold
Q2 2026—−$15.9M24 sales · all on a plan
Q1 2026—−$41.1M52 sales · 50 on a plan
Q4 2025—−$22M32 sales · all on a plan
Q3 2025—−$15M29 sales · all on a plan
Q2 2025——
Q1 2025—−$17.9M21 sales · all on a plan
Q4 2024—−$16.5M34 sales · all on a plan
Q3 2024—−$19.8M30 sales · all on a plan
Largest sale
−$3.9M of KRYS by Krishnan Suma (President, R&D · Director) on Jun 04, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Thomas John Charles10b5-1

    EVP, General Counsel

    −$347.3K

    Jun 25, 2026

    1,000 sh · $347.27

  • Krishnan Suma10b5-1

    President, R&D · Director

    −$3.9M

    Jun 04, 2026

    12,729 sh · $307.81

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$3.5M

    Jun 04, 2026

    11,461 sh · $307.68

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$1.5M

    Jun 04, 2026

    4,830 sh · $308.47

  • Krishnan Suma10b5-1

    President, R&D · Director

    −$1.2M

    Jun 04, 2026

    3,803 sh · $308.89

  • Krishnan Suma10b5-1

    President, R&D · Director

    −$868.2K

    Jun 04, 2026

    2,801 sh · $309.95

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$861.6K

    Jun 04, 2026

    2,784 sh · $309.49

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$823.3K

    Jun 04, 2026

    2,652 sh · $310.43

  • Krishnan Suma10b5-1

    President, R&D · Director

    −$634K

    Jun 04, 2026

    2,039 sh · $310.94

  • Krishnan Suma10b5-1

    President, R&D · Director

    −$414K

    Jun 04, 2026

    1,348 sh · $307.09

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$300.2K

    Jun 04, 2026

    964 sh · $311.36

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$193.4K

    Jun 04, 2026

    640 sh · $302.24

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$180.4K

    Jun 04, 2026

    589 sh · $306.33

  • Krishnan Suma10b5-1

    President, R&D · Director

    −$179.2K

    Jun 04, 2026

    593 sh · $302.25

  • Krishnan Krish S10b5-1

    President and CEO · Director

    −$165.8K

    Jun 04, 2026

    544 sh · $304.81

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Krystal Biotech, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Pittsburgh, PA
Listed on
Nasdaq
SEC Central Index Key
0001711279

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought KRYS

What the stock actually did in the 90 days following each open-market purchase

Don't check KRYS — let it ping you

Get told the moment an insider moves on KRYS

Pro watches Krystal Biotech, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add KRYS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track KRYS on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read KRYS insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

RAREFOLDACADPTCTMEDPDNLIVEEVTEMALKSAPLSARVNBBIO
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are KRYS insiders buying or selling?
Between Sep 04, 2026 and Sep 04, 2026, 2 Krystal Biotech, Inc. insiders made no open-market purchases and 24 sales worth $17.5M, a net sale of $17.5M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much KRYS stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 6 Krystal Biotech, Inc. insiders made no open-market purchases and 222 sales worth $148.2M. 220 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 137 sales ($94.1M). The largest sale was Krishnan Suma selling $3.9M on Jun 04, 2026.
What was the largest recent KRYS insider trade?
Krishnan Krish S (President and CEO · Director) sold $1.4M of KRYS stock on Sep 04, 2026 at about $357.57 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy KRYS shares?
No open-market purchase by a Krystal Biotech, Inc. insider appears in the filings from Sep 04, 2026 to Sep 04, 2026 — every recorded open-market transaction in that period was a sale.
Where does KRYS insider trading data come from?
From the Form 4 filings Krystal Biotech, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.